JP2022538117A5 - - Google Patents

Info

Publication number
JP2022538117A5
JP2022538117A5 JP2021576582A JP2021576582A JP2022538117A5 JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5 JP 2021576582 A JP2021576582 A JP 2021576582A JP 2021576582 A JP2021576582 A JP 2021576582A JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538117A (ja
JP7788859B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/039687 external-priority patent/WO2020264211A1/en
Publication of JP2022538117A publication Critical patent/JP2022538117A/ja
Publication of JP2022538117A5 publication Critical patent/JP2022538117A5/ja
Priority to JP2025107324A priority Critical patent/JP2025175994A/ja
Application granted granted Critical
Publication of JP7788859B2 publication Critical patent/JP7788859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576582A 2019-06-26 2020-06-25 がんを処置するための抗ｃｄ３３抗体 Active JP7788859B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107324A JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867032P 2019-06-26 2019-06-26
US62/867,032 2019-06-26
PCT/US2020/039687 WO2020264211A1 (en) 2019-06-26 2020-06-25 Anti-cd33 antibodies for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107324A Division JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Publications (3)

Publication Number Publication Date
JP2022538117A JP2022538117A (ja) 2022-08-31
JP2022538117A5 true JP2022538117A5 (enExample) 2023-07-03
JP7788859B2 JP7788859B2 (ja) 2025-12-19

Family

ID=74059823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576582A Active JP7788859B2 (ja) 2019-06-26 2020-06-25 がんを処置するための抗ｃｄ３３抗体
JP2025107324A Pending JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107324A Pending JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Country Status (6)

Country Link
US (1) US20220251192A1 (enExample)
EP (1) EP3990022A4 (enExample)
JP (2) JP7788859B2 (enExample)
CN (1) CN114401744B (enExample)
CA (1) CA3149683A1 (enExample)
WO (1) WO2020264211A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
JP7788859B2 (ja) * 2019-06-26 2025-12-19 メモリアル スローン ケタリング キャンサー センター がんを処置するための抗ｃｄ３３抗体
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
JP2023527385A (ja) * 2020-05-27 2023-06-28 メモリアル スローン ケタリング キャンサー センター 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用
EP4608871A1 (en) * 2022-10-26 2025-09-03 Memorial Sloan-Kettering Cancer Center Cd33 antibody compositions for treating alzheimer's disease
CN116375874B (zh) * 2023-04-14 2023-12-26 上海精翰生物科技有限公司 一种cd33抗体及其应用
CN118580357A (zh) * 2024-08-07 2024-09-03 上海交通大学医学院附属仁济医院 一种cd33特异性单克隆抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
HUE026914T2 (en) * 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
KR20170004003A (ko) * 2014-05-20 2017-01-10 이뮤노젠 아이엔씨 급성 골수성 백혈병의 특성화 및 치료 방법
US9777061B2 (en) * 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
KR102638104B1 (ko) * 2014-07-25 2024-02-20 메모리얼 슬로안 케터링 캔서 센터 이특이적 her2 및 cd3 결합 분자
AU2016337525B2 (en) * 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3484516A4 (en) * 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center MULTIPLE SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOP BINDING FOR TREATING CANCER
RU2019114863A (ru) * 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
WO2018204873A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (sada) technologies
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画
ES3057687T3 (en) * 2017-07-06 2026-03-04 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
CA3075896A1 (en) * 2017-09-22 2019-03-28 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
US20190153096A1 (en) * 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
JP7788859B2 (ja) * 2019-06-26 2025-12-19 メモリアル スローン ケタリング キャンサー センター がんを処置するための抗ｃｄ３３抗体

Similar Documents

Publication Publication Date Title
JP2022546572A5 (enExample)
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
JP2022525435A5 (enExample)
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
JP5085005B2 (ja) 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
JP2023523584A5 (enExample)
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
Welt et al. Phase I study of anticolon cancer humanized antibody A33
JP5155356B2 (ja) モノクローナル抗体ｈＰＡＭ４
KR101002443B1 (ko) Ｒｓ7 항체
JP2020523029A5 (enExample)
JP2021517816A5 (enExample)
Chester et al. Engineering antibodies for clinical applications in cancer
JP2023537002A5 (enExample)
JP2022540611A5 (enExample)
JP2020534017A5 (enExample)
CA3062335A1 (en) Use of anti-b7h3 antibodies for treating cancer in the central nervous system
Oriuchi et al. Current status of cancer therapy with radiolabeled monoclonal antibody
JP2024530166A5 (enExample)
CN115103633B (zh) 使用多种成像剂的成像方法
CN115379848A (zh) 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
Shapiro Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
Lindland et al. Preclinical evaluation of PTK7-targeted radionuclide therapy
JP2024531913A5 (enExample)
KR20250017214A (ko) 항cd44v6 항체 및 이들의 cd44v6 과발현 암 치료의 용도